Lannett Company, Inc. (NYSE: LCI) today announced that it launched four products in June 2018, bringing to seven the total number of products launched since January 1, 2018.

The June product launches include Diclofenac Sodium ER Tablets, Levofloxacin Oral Solution, Memantine Hydrochloride Tablets and Metolazone Tablets. Total U.S. sales of the combined products were nearly $100 million for the 12 months ended May 2018, according to IMS.

"With these four products, we have commenced seven launches since the beginning of the current calendar year," said Tim Crew, chief executive officer of Lannett. "I'm pleased with the progress that our cross-functional teams are making with regard to launching the commercially ready products in our pipeline. We expect to commence marketing several additional products shortly and a number of others over the course of fiscal 2019."

About Lannett Company, Inc.: Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.